In addition to PCa, Nox5 is also expressed at elevated levels in breast, colon, lung, brain, and ovary cancer, malignant melanoma and non‐Hodgkin lymphoma and has also been implicated in the development of esophageal adenocarcinoma 40, 41, 66. Here, NOX5 is linked to posterior cortical atrophy.